|
Total no of patients (%)
|
101 (100)
|
67 (66.3)
|
34 (33.7)
| |
37 (36.6)
|
32 (31.7)
|
23 (22.8)
|
9 (8.9)
| |
|
Gender Male, no (%)
|
70 (69.3)
|
48 (47.5)
|
22 (21.8)
|
0.500
|
29 (28.7)
|
20 (19.8)
|
15 (14.9)
|
6 (5.9)
|
0.505
|
|
Age, years
|
65.3 (12.8)
|
63.8 (11.5)
|
68.3 (14.8)
|
0.047
|
60.2 (12.8)
|
66.8 (12.6)
|
71.2 (10.7)
|
66.0 (11.8)
|
0.009
|
|
Cardiovascular risk factors
|
|
Smoking, no (%)
|
28 (27.7)
|
19 (18.8)
|
9 (8.91)
|
1.000
|
11 (10.9)
|
11 (10.9)
|
3 (3.0)
|
3 (3.0)
|
0.335
|
|
Diabetes mellitus, no (%)
|
21 (20.8)
|
10 (9.9)
|
11(10.9)
|
0.067
|
4 (4.0)
|
7 (6.9)
|
8 (7.9)
|
2 (2.0)
|
0.171
|
|
Dyslipidaemia, no (%)
|
30 (29.7)
|
22 (21.8)
|
8 (7.9)
|
0.367
|
8 (7.9)
|
10 (9.9)
|
9 (8.9)
|
3 (3.0)
|
0.526
|
|
Hypertension, no (%)
|
58 (57.4)
|
40 (39.6)
|
18 (17.8)
|
0.531
|
18 (17.8)
|
17 (16.8)
|
16 (15.8)
|
7 (6.9)
|
0.229
|
|
Past medical history
|
|
Previous MI, no (%)
|
20 (19.8)
|
15 (14.9)
|
5 (5.0)
|
0.436
|
3 (3.0)
|
4 (4.0)
|
8 (7.9)
|
5 (5.0)
|
0.002
|
|
Previous CAD, no (%)
|
29 (28.7)
|
21 (20.8)
|
8 (7.9)
|
0.490
|
4 (4.0)
|
9 (8.9)
|
10 (9.9)
|
6 (5.9)
|
0.002
|
|
Previous CHF, no (%)
|
3 (3.0)
|
2 (2.0)
|
1 (1.0)
|
1.000
|
0 (0.0)
|
1 (1.0)
|
1 (1.0)
|
1 (1.0)
|
0.340
|
|
Renal failure, no (%)
|
12 (11.9)
|
8 (7.9)
|
4 (4.0)
|
1.000
|
3 (3.0)
|
2 (2.0)
|
5 (5.0)
|
2 (2.0)
|
0.210
|
|
COPD no, no (%)
|
11 (10.9)
|
9 (8.9)
|
2 (2.0)
|
0.326
|
3 (3.0)
|
6 (5.9)
|
0 (0.0)
|
2 (2.0)
|
0.096
|
|
Baseline characteristics on admission
|
|
HR (bpm)
|
79.7 (15.6)
|
78.5 (16.0)
|
82.0 (14.5)
|
0.297
|
70.6 (15)
|
80.4 (12.3)
|
87.8 (13.4)
|
93.8 (11.7)
|
< 0.001
|
|
Systolic BP (mmHg)
|
106.8 (19.5)
|
111.8 (17.9)
|
96.3 (18.7)
|
< 0.001
|
106.9 (16.4)
|
103.16 (20.7)
|
108.9 (21.2)
|
114.0 (22.2)
|
0.462
|
|
MAP (mmHg)
|
73.0 (13.0)
|
77.7 (10.3)
|
63.7 (12.9)
|
< 0.001
|
72.5 (12.4)
|
73.7 (15.3)
|
71.4 (9.5)
|
77.0 (15.0)
|
0.720
|
|
PaO2/FiO2 ratio, med (IQR)
|
143 (98–233)
|
154 (98–271)
|
105 (83–173)
|
0.036
|
157.9 (105–241)
|
165 (83–286)
|
105 (83–143)
|
128 (75–278)
|
0.138
|
|
GCS, med (IQR)
|
3 (3–15)
|
11 (3–15)
|
3 (3–3)
|
< 0.001
|
3 (3–4)
|
3 (3–14.5)
|
14 (3–15)
|
3 (3–15)
|
0.071
|
|
Serum creatinine (μmol/L), med (IQR)
|
116 (87–157)
|
102 (84–129)
|
156 (115–203)
|
< 0.001
|
101 (71–126)
|
116 (95–155)
|
140 (112–191)
|
135 (117–144)
|
0.012
|
|
SOFA score
|
8.4 (3.3)
|
7.4 (2.9)
|
10.4 (3.1)
|
< 0.001
|
8.6 (2.6)
|
8.5 (3.5)
|
8.3 (3.4)
|
8.0 (5.2)
|
0.953
|
|
Indication for ICU admission
|
|
OHCA, no (%)
|
37 (36.6)
|
26 (25.7)
|
11 (10.9)
|
0.663
| | | | | |
|
Downtime before ROSC (min), (IQR)
|
20 (15–30)
|
15 (10–20)
|
35 (30–40)
|
< 0.001
| | | | | |
|
IHCA, no (%)
|
32 (31.7)
|
19 (18.8)
|
13 (12.7)
|
0.368
| | | | | |
|
Downtime before ROSC (min), (IQR)
|
10 (5–20)
|
9 (5–14)
|
15 (5–42)
|
0.214
| | | | | |
|
Cardiogenic shock, no (%)
|
23 (22.8)
|
14 (13.9)
|
9 (8.9)
|
0.617
| | | | | |
|
Acute pulmonary oedema, no (%)
|
9 (8.9)
|
8 (7.9)
|
1 (1.0)
|
0.266
| | | | | |
